REG - Venture Life Group - Exercise of Share Options & Total Voting Rights

Venture LifeAnnouncement

18/12/2025 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251218:nRSR1816Ma&default-theme=true

RNS Number : 1816M  Venture Life Group PLC  18 December 2025

18 December 2025

 

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

Exercise of Share Options & Total Voting Rights

 

Venture Life Group PLC (AIM: VLG), a recognised leader in proactive healthy,
product innovation, development, and commercialisation within the global
consumer healthcare sector, announces that it has issued 201,500 ordinary
shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") in
accordance with an exercise of share options by a number of employees, subject
to admission to trading on AIM.

Application will be made to the London Stock Exchange for the 201,500 new
Ordinary Shares to be admitted to trading on AIM ("Admission") and it is
expected that Admission will become effective, and trading will commence at
8.00 a.m. on 24 December 2025.

Following Admission, the total number of Ordinary Shares in issue will be
128,253,812, with 863,989 Ordinary Shares held in treasury. Therefore, the
total number of voting rights will be 127,389,823. This figure may be used by
shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the share capital of the Company under the FCA's Disclosure
and Transparency Rules.

 

For further information, please contact:

Venture Life Group PLC
                                             +44 (0)
1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and Broker)
                         +44 (0) 20 7720 0500

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in
the UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, plus the
Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels and are sold globally.
In the UK,  Ireland and the USA these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEQVLFFELLFFBD



            Copyright 2019 Regulatory News Service, all rights reserved